Skip to content

Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries

A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02064894
Enrollment
501
Registered
2014-02-17
Start date
2013-07-08
Completion date
2015-06-22
Last updated
2017-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal Injury

Keywords

children, analgesia, musculoskeletal injury, emergency, opioids

Brief summary

Pain management for children presenting to the emergency department (ED) with an injured limb is often under-treated, even though it is known that broken arms and legs cause moderate to severe pain. Further, children are less likely to receive appropriate pain medicine than adults with similar injuries. This study aims to improve the pain treatment of children who present to the ED with a suspected fracture, or broken bone or severe sprain. The investigators will compare the use of 3 different possible medication combinations (ibuprofen alone, oral morphine alone, or combined ibuprofen and oral morphine) to determine which combination is the best at treating children's pain. The investigators also plan to verify the safety of using these different drugs to treat children's pain. The investigators strongly believe that children's pain should be optimally treated in the ED. Adequately relieving children's pain is crucial, as inadequate pain treatment can have both short and longterm effects on the child. It also generates unnecessary stress for both the child and their caregivers/parents. Given this knowledge, the investigators feel that their study has the potential to impact care provided in EDs, and improve pain management safely, for children.

Detailed description

Rationale. Musculoskeletal trauma (MSK-T) in children is very common and almost universally painful. Standards for children's pain management of MSK-T in the Emergency Department (ED) vary greatly between Canadian hospitals and, overall, pain is very poorly treated. This inadequate pain treatment can have significant acute and chronic negative effects. Previous studies have determined that monotherapy with ibuprofen, the most commonly prescribed oral analgesic in the ED, is likely providing inadequate pain management for children. In response to this problem, clinicians have turned back to classic oral opioids (eg morphine) and are experimenting with combination therapies. To date, few studies have focused on the efficacy of a combination of a non-steroidal anti-inflammatory drug (NSAID) (eg ibuprofen) and an opioid (eg morphine). Such a combination of analgesics is known to potentiate pain relief by blocking it at the level of both the peripheral and the central nervous system. By combining two drugs with different mechanisms of action, we may be able to provide additive analgesic effects. To our knowledge, no studies have ever studied the efficacy and safety of this combination of medication for MSK-T in pediatric EDs. Primary Hypothesis: For children with a MSK-T in the ED, the addition of morphine to ibuprofen is safe and provides better pain relief than either of the two drugs alone. Primary Research Question: For children with a MSK-T in the ED, is a combination of oral morphine (0.2 mg/kg) and oral ibuprofen (10 mg/kg) more efficacious than either of the two drugs, alone, in decreasing pain scores to \<30 mm, 60 minutes after administration? Methods. Design: This study is a double-blind, placebo-controlled, two center, three-arm, randomized clinical trial (RCT). Patients will be randomized to receive either: (a) ibuprofen (10mg/kg) + placebo or (b) morphine (0.2 mg/kg) + placebo or (c) morphine (0.2mg/kg) + ibuprofen (10mg/kg). Setting: Stollery Children's Hospital (Edmonton, AB) and CHU Ste.Justine's pediatric hospital (Montreal, PQ). Inclusion criteria: We will include children: (a) between the ages of 8 and 17 years; (b) visiting the ED with an injured upper or lower limb that is neither obviously deformed, nor neurovascularly compromised, (c) with a self-reported pain score \>30 mm on a 0 to100mm Visual Analogue Scale (VAS), where 0 mm corresponds to no pain and 100 mm to the worst pain the child has experienced, and (d) who understand French or English. Sample Size: Based on previous studies, we expect that between 25-52% (Clark et al., 2007, Le May et al., 2013) of children will achieve a VAS \< 30 mm at 60 minutes in the ibuprofen arm. We have conservatively set the proportion of children with VAS \< 30 mm at 60 min to 50%. A sample size of 500 will be then necessary to provide at least 80% power to detect a 20% absolute difference in proportion using a two-tailed with an alpha level of 5%. In order to ensure an overall alpha level of 5%, a Bonferroni correction has been applied in order to take into account the 3 pairwise comparisons that will be performed. Primary Outcome and Measurement: The primary outcome measure will be pain intensity score under 30 mm at 60-minutes after medication administration, using the VAS). Primary Safety Outcomes: We will also assess clinical measures of safety by monitoring oxygen saturation at 30 minutes intervals, up until 120 minutes. Level of sedation/alertness, as well as the respiratory rate, of each child will be monitored at set time points in the study, up until 120 minutes. Participating children will be followed up (via phone call) at 24 hours, to record any latent side effects or adverse events. Further, acceptability of the intervention will be assessed. Relevance: Our proposed work will be the first RCT to investigate if there is some additive effect of a bi-therapy of pain with ibuprofen and morphine. In summary, currently available research supports ibuprofen as the monotherapy agent of choice. However, given concerns regarding its ability to provide adequate relief on its own, smaller studies looked at morphine as a possible alternative combined to ibuprofen. Very few studies of analgesic combinations exist, and as such, we have yet to identify the optimal ED pain management strategy for children with MSK-T. A larger trial with careful control over principal sources of bias and a rigorous approach to safety data collection will provide clinicians with strong evidence regarding efficacy and safety on new therapeutic strategies for pain management related to MSK-T in the pediatric EDs.

Interventions

DRUGoral morphine and oral ibuprofen

The combination of oral morphine and oral ibuprofen is one of the Experimental arm group

Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study

oral ibuprofen combine to a placebo is the active comparator

Sponsors

St. Justine's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Between the ages of 6 and 17 years * Presenting to the ED with a musculoskeletal (MSK) trauma to either of the upper or lower limbs that is neither obviously deformed, nor neurovascularly compromised * Self-reported pain score \>29 mm on a 0 to 100mm Visual Analogue Scale (VAS) * Able to understand French or English.

Exclusion criteria

* Known allergy to morphine, ibuprofen, or artificial colouring * MSK trauma that are suspected to be due to child abuse, as determined by the triage nurse * Inability to self-report pain * Chronic pain issues that require daily analgesic use * NSAID or opioid analgesic use within three hours prior to presentation to triage (Exception of acetaminophen) * Trauma to more than one limb (except fingers and toes) * Known hepatic or renal disease/dysfunction * Known bleeding disorder * Neuro-cognitive disability that precludes patients from assenting and participating to the study. * Known history of snoring consistently for the past 5 nights

Design outcomes

Primary

MeasureTime frameDescription
Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm60 minutes post-analgesiaPercentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes. The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=No Pain; Score of 100=Worst imaginable pain

Secondary

MeasureTime frameDescription
Serious Adverse Event - Side Effects and Serious Adverse Events60, 90 and 120 minutesTo verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study

Countries

Canada

Participant flow

Pre-assignment details

Assessed for eligibility (n=5127) Excluded (n=4626) * Not meeting inclusion criteria (n=1670) * Excluded as per exclusion criteria (n=663) * Declined to participate (n=874) * Not evaluated (n=1144) * Other reasons (n=275) Randomized (n=501)

Participants by arm

ArmCount
Oral Morphine and Oral Ibuprofen
Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
91
Morphine and Placebo of Ibuprofen
Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
188
Ibuprofen and Placebo of Morphine
Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator
177
Total456

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyWithdrawal by Subject43102115

Baseline characteristics

CharacteristicOral Morphine and Oral IbuprofenMorphine and Placebo of IbuprofenIbuprofen and Placebo of MorphineTotal
Age, Continuous12.2 years
STANDARD_DEVIATION 2.6
11.7 years
STANDARD_DEVIATION 2.7
12.0 years
STANDARD_DEVIATION 2.7
11.9 years
STANDARD_DEVIATION 2.7
Age, Customized
12-17
52 Participants103 Participants103 Participants258 Participants
Age, Customized
6-11
39 Participants85 Participants74 Participants198 Participants
Injury location - n(%)
Ankle
21 Participants38 Participants37 Participants96 Participants
Injury location - n(%)
Elbow
6 Participants14 Participants10 Participants30 Participants
Injury location - n(%)
Foot
6 Participants21 Participants12 Participants39 Participants
Injury location - n(%)
Forearm
6 Participants11 Participants12 Participants29 Participants
Injury location - n(%)
Knee
15 Participants25 Participants27 Participants67 Participants
Injury location - n(%)
Other
13 Participants51 Participants54 Participants118 Participants
Injury location - n(%)
Wrist
24 Participants28 Participants25 Participants77 Participants
Injury type - n(%)
Fracture
43 Participants67 Participants65 Participants175 Participants
Injury type - n(%)
Missing
0 Participants4 Participants0 Participants4 Participants
Injury type - n(%)
Soft tissue injury
48 Participants117 Participants112 Participants277 Participants
Sex: Female, Male
Female
38 Participants82 Participants84 Participants204 Participants
Sex: Female, Male
Male
53 Participants106 Participants93 Participants252 Participants
VAS score at Baseline - Continuous60.9 units on a scale
STANDARD_DEVIATION 15.5
60.8 units on a scale
STANDARD_DEVIATION 15.8
61.0 units on a scale
STANDARD_DEVIATION 17.1
60.9 units on a scale
STANDARD_DEVIATION 16.2
VAS score at Baseline stratified by pain intensity
30-69 mm
64 Participants128 Participants121 Participants313 Participants
VAS score at Baseline stratified by pain intensity
> 69 mm
27 Participants60 Participants56 Participants143 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
6 / 9139 / 18838 / 177
serious
Total, serious adverse events
0 / 910 / 1880 / 177

Outcome results

Primary

Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm

Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes. The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=No Pain; Score of 100=Worst imaginable pain

Time frame: 60 minutes post-analgesia

ArmMeasureValue (NUMBER)
Oral Morphine and Oral IbuprofenPain Intensity - Percentage of Children Who Achieved VAS < 30 mm33.0 Percentage of participants
Morphine and Placebo of IbuprofenPain Intensity - Percentage of Children Who Achieved VAS < 30 mm29.3 Percentage of participants
Ibuprofen and Placebo of MorphinePain Intensity - Percentage of Children Who Achieved VAS < 30 mm29.9 Percentage of participants
p-value: 0.81Cochran-Mantel-Haenszel
Secondary

Serious Adverse Event - Side Effects and Serious Adverse Events

To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study

Time frame: 60, 90 and 120 minutes

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Oral Morphine and Oral IbuprofenSerious Adverse Event - Side Effects and Serious Adverse EventsSide effects6 Participants
Oral Morphine and Oral IbuprofenSerious Adverse Event - Side Effects and Serious Adverse EventsSerious adverse event0 Participants
Morphine and Placebo of IbuprofenSerious Adverse Event - Side Effects and Serious Adverse EventsSide effects39 Participants
Morphine and Placebo of IbuprofenSerious Adverse Event - Side Effects and Serious Adverse EventsSerious adverse event0 Participants
Ibuprofen and Placebo of MorphineSerious Adverse Event - Side Effects and Serious Adverse EventsSide effects38 Participants
Ibuprofen and Placebo of MorphineSerious Adverse Event - Side Effects and Serious Adverse EventsSerious adverse event0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026